IRICoR will participate at the LES 2022 annual meeting to be held from October 16 to 19, 2022, in San Francisco.
This event is an opportunity for intellectual property and licensing professionals to network, collaborate and discuss some of the most critical issues facing the industry today. LES 2022 annual meeting offers more than 30 sessions led by industry experts and […]

IRICoR is very pleased to announce the appointment of Nioucha Rodrigue, as a Financial Controller. In this role, Mrs Rodrigue will collaborate in the planning, development and implementation of IRICoR’s budget as well as in the forecasting process. She will also play an advisory role in optimizing the management of financial resources.
Mrs Rodrigue joins the IRICoR team with more than 10 years of […]

IRICoR is very pleased to announce the appointmentas of June 2, 2022 of Claude Larose, as Vice-President, Business Development and new member of IRICoR’s Management team. In this role, Mr. Larose will be primarily responsible for establishing links and concluding agreements with entities outside IRICoR, both in the public and private sectors, with a view to exit events for projects […]

IRICoR announces its participation in the BIO 2022 international convention to be held from June 13 to 16, 2022 in San Diego. This industry event aims to create business opportunities among life science players from all over the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, in particular through the […]

 
IRICoR attend the AUTM Canadian Region Meeting, May 16-18, 2022.
AUTM’s Regional Meeting invites technology transfer professionals from around the globe to network, make deals and gain valuable insights from world-class speakers and panels.
If you would like to meet with IRICoR at AUTM 2022, please contact Jean-louis Brochu, M.Sc., Senior Intellectual Property Manager, who will represent IRICoR at this event:

By email : 

As part of Effervescence, an event organized by Montréal Invivo and bringing together major players in the life sciences community, Pierre Fitzgibbon Minister of Economy and Innovation presented the Stratégie québécoise des sciences de la vie 2022-2025

IRICoR is delighted with this announcement. Challenged by COVID-19, stakeholders in the sector have mobilized and adapted to respond to the health crisis, and […]

IRICoR is delighted with the announcement made today by Epitopea, a transatlantic cancer immunotherapeutics company, on a $13.6M seed investment from a transatlantic syndicate of top-tier life sciences investors, including AdventLifeSciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ.
The company’s proprietary technology provides an innovative approach to identifying shared, aberrantly expressed tumour specific antigens, known as […]

IRICoR is delighted with the announcement made today by ONO Pharmaceutical Co., Ltd. (“ONO”), one of Japan’s largest clinical-stage pharmaceutical companies, on signing a collaboration agreement with Domain Therapeutics S.A. (“Domain”) and University of Montreal (“UdeM”), to discover new small molecules targeting G protein-coupled receptors (GPCRs) in the treatment of a metabolic disease.
“Very early on, we identified and supported this […]

 
Aimed at research and life sciences professionals, IRICoR is very excited to invite you to its next workshop on intellectual property.
 
To mark World Intellectual Property Day, please join us on April 26, from 12:00 pm to 1:30 pm, during lunch break for this webinar on intellectual property, entitled: Patents: practical and strategic considerations
 
Our guest speaker, Mr. Alain Dumont, […]

It is with pleasure that Mrs. Nadine Beauger, President and CEO of IRICoR, went “Under the microscope” of IVADO. “Under the microscope” is a project aimed at highlighting members of its community through short portraits.
Extract from the interview: “Our flexible project development model allows us to identify complementary expertise to include artificial intelligence know-how in drug discovery projects.”
Read the interview […]